Can-Fite BioPharma American Depositary Shares
CANF
12 hedge funds and large institutions have $2.43M invested in Can-Fite BioPharma American Depositary Shares in 2021 Q3 according to their latest regulatory filings, with 5 funds opening new positions, 1 increasing their positions, 1 reducing their positions, and 4 closing their positions.
713% more capital inflows, than outflows
Capital inflows: $2.21M | Capital outflows: $272K
25% more first-time investments, than exits
New positions opened: 5 | Existing positions closed: 4
9% more funds holding
Funds holding: 11 → 12 (+1)
5% more ownership
Funds ownership: 2.29% → 7.29% (+5%)
0% more repeat investments, than reductions
Existing positions increased: 1 | Existing positions reduced: 1
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Armistice Capital
New York
|
+$1.72M |
| 2 |
Acadian Asset Management
Boston,
Massachusetts
|
+$226K |
| 3 |
Renaissance Technologies
New York
|
+$184K |
| 4 |
Fifth Third Bancorp
Cincinnati,
Ohio
|
+$59K |
| 5 |
Morgan Stanley
New York
|
+$23.2K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
StoneX Group
New York
|
-$91K |
| 2 |
Citadel Advisors
Miami,
Florida
|
-$88K |
| 3 |
Cetera Advisor Networks
El Segundo,
California
|
-$52.3K |
| 4 |
Two Sigma Securities
New York
|
-$23K |
| 5 |
UBS Group
Zurich,
Switzerland
|
-$18K |
CANF Hedge Fund Activity: Q3 2021 in Review
12 of the 5,730 institutional investors tracked by Wall St. Rank reported a position in Can-Fite BioPharma American Depositary Shares (CANF) for Q3 2021, worth a combined $2.43M — up 132% from $1.05M a quarter earlier.
Buyers outnumbered sellers: 5 funds opened new CANF positions and 4 closed out — a net gain of 1 holder — while 1 added to existing stakes and 1 trimmed.
The largest buyer was Armistice Capital, opening a new position worth an estimated $1.72M. The largest seller was StoneX Group, exiting entirely with an estimated $91K sold.
- 12 institutional investors held Can-Fite BioPharma American Depositary Shares (CANF) as of Q3 2021, up from 11 in Q2 2021.
- Funds reported $2.43M of Can-Fite BioPharma American Depositary Shares stock for Q3 2021, up 132% quarter-over-quarter.
- 5 funds opened new Can-Fite BioPharma American Depositary Shares positions in Q3 2021 and 4 closed out, a net change of +1 holder.
- The largest Can-Fite BioPharma American Depositary Shares buyer in Q3 2021 was Armistice Capital, an estimated $1.72M added.
- The largest Can-Fite BioPharma American Depositary Shares seller in Q3 2021 was StoneX Group, an estimated $91K sold.
Based on aggregated 13F filings for Q3 2021.